Omega Therapeutics, Inc., a biotechnology company, develops genomic medicines to cure diseases. The company focuses on precision tuning to activate the human genome's native capacity to treat and cure diseases. It engages in designing, engineering, and manufacturing Epigenomic Controllers to target the GenomStats for the cell types of interest, with the ability to downregulate or upregulate genomic activity for therapeutic effect. Omega Therapeutics, Inc. was formerly known as VL42, Inc. and changed its name to Omega Therapeutics, Inc. in July 2017. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.